Promising Anticancer Therapy: Combination of Immune Checkpoint Inhibitors and Molecular-targeted Agents

Overview

Journal Hepatobiliary Surg Nutr

Publisher AME Publishing Company

Date 2020 Dec 10

PMID 33299833

Citations 4

Authors

Toshiharu Sakurai

Naoshi Nishida

Masatoshi Kudo

Affiliations

Soon will be listed here.

Citing Articles

Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review.

Arshi A, Mahmoudi E, Raeisi F, Dehghan Tezerjani M, Bahramian E, Ahmed Y Front Immunol. 2024; 15:1446937.

PMID: 39257589 PMC: 11384988. DOI: 10.3389/fimmu.2024.1446937.

The prognostic significance and immune characteristics of bone morphogenetic proteins (BMPs) family: A pan-cancer multi-omics analysis.

Chen C, Zhang Y, Lin Y, Shen C, Zhang Z, Wu Z Technol Health Care. 2024; 32(6):4123-4175.

PMID: 39031404 PMC: 11613112. DOI: 10.3233/THC-232004.

The prognostic values and immune characteristics of polo-like kinases (PLKs) family: A pan-cancer multi-omics analysis.

Shen C, Wang T, Li K, Fu C, Yang S, Zhang Z Heliyon. 2024; 10(7):e28048.

PMID: 38560150 PMC: 10979165. DOI: 10.1016/j.heliyon.2024.e28048.

Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy.

Ding Y, Han X, Sun Z, Tang J, Wu Y, Wang W Front Oncol. 2021; 11:691380.

PMID: 34527576 PMC: 8435785. DOI: 10.3389/fonc.2021.691380.

References

Greten F, Eckmann L, Greten T, Park J, Li Z, Egan L . IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004; 118(3):285-96. DOI: 10.1016/j.cell.2004.07.013. View

Sakurai T, He G, Matsuzawa A, Yu G, Maeda S, Hardiman G . Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell. 2008; 14(2):156-65. PMC: 2707922. DOI: 10.1016/j.ccr.2008.06.016. View

Bui J, Uppaluri R, Hsieh C, Schreiber R . Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res. 2006; 66(14):7301-9. DOI: 10.1158/0008-5472.CAN-06-0556. View

Kudo M . Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma. Liver Cancer. 2019; 8(1):1-11. PMC: 6388565. DOI: 10.1159/000496277. View

Maeda S, Kamata H, Luo J, Leffert H, Karin M . IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005; 121(7):977-90. DOI: 10.1016/j.cell.2005.04.014. View

Kang H, Chung D, Sung C, Yoo S, Yu E, Kim N . SHP2 is induced by the HBx-NF-κB pathway and contributes to fibrosis during human early hepatocellular carcinoma development. Oncotarget. 2017; 8(16):27263-27276. PMC: 5432333. DOI: 10.18632/oncotarget.15930. View

Kudo M . Combination Cancer Immunotherapy in Hepatocellular Carcinoma. Liver Cancer. 2018; 7(1):20-27. PMC: 5892358. DOI: 10.1159/000486487. View

Cui S, Shi W, Song Z, Wang S, Yu X, Gao Z . Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Oncotarget. 2016; 7(24):36767-36782. PMC: 5095038. DOI: 10.18632/oncotarget.9168. View

Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T . Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012; 209(6):1201-17. PMC: 3371732. DOI: 10.1084/jem.20112741. View

10.

Kudo M . Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials. Liver Cancer. 2019; 8(4):221-238. PMC: 6738201. DOI: 10.1159/000501501. View

11.

Sakurai T, Yada N, Hagiwara S, Arizumi T, Minaga K, Kamata K . Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma. Cancer Sci. 2017; 108(10):1996-2003. PMC: 5623735. DOI: 10.1111/cas.13341. View

12.

Ebert P, Cheung J, Yang Y, McNamara E, Hong R, Moskalenko M . MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. Immunity. 2016; 44(3):609-621. DOI: 10.1016/j.immuni.2016.01.024. View

13.

Ran H, Tsutsumi R, Araki T, Neel B . Sticking It to Cancer with Molecular Glue for SHP2. Cancer Cell. 2016; 30(2):194-196. PMC: 5558882. DOI: 10.1016/j.ccell.2016.07.010. View

14.

Leung C, Tong M, Chung K, Zhou L, Che N, Tang K . Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma. Hepatology. 2019; 72(1):155-168. DOI: 10.1002/hep.30989. View

15.

Nishida N, Kitano M, Sakurai T, Kudo M . Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma. Dig Dis. 2015; 33(6):771-9. DOI: 10.1159/000439102. View